‘No path forward’ with Teva, Mylan pledges amid warring roadshows

Carly Helfand

Late last month, kicked off a roadshow to meet shareholders of its buyout target, , and find out what price it'll need to put forth to convince them to support a deal. As starts up its own roadshow, its message is clear: It's categorically opposed to a tie-up with the Israeli drugmaker, and investors can't force one, either.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS